Cargando…
外周血游离DNA的动态变化预测TKI治疗EGFR突变肺腺癌患者的疗效
BACKGROUND AND OBJECTIVE: The tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation may have a positive effect, but most patients may develop drug resistance, therefore, the detection of the developing time in drug resi...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754570/ https://www.ncbi.nlm.nih.gov/pubmed/31526460 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.03 |